•		10.7
Α	adrenaline	alprostadil, intraurethral 121
acanthosis nigricans 100	effect on potassium levels 185	amenorrhoea
acarbose 203	secretion in congenital adrenal	primary 95–8
acidosis, effect on potassium levels	hyperplasia 72	prolactinoma 80,81
185	secretion by	secondary 99–103
acromegaly 75-6,79	phaeochromocytoma 167	amiloride 180, 187, 217, 218
hypertension 165	adrenarche 131	use in Liddle's syndrome 187
investigation 76,77	adrenergic postprandial syndrome	use in lithium-induced diabetes
management 76-8	(APS) 200-1	insipidus 217,218
activated charcoal, use in thyrotoxic	adrenocorticotrophic hormone	aminoglutethimide therapy,
crisis 41	(ACTH)	Cushing's disease 66
acute coronary syndromes,	levels in adrenal insufficiency	aminoglycoside antibiotics, renal
hypokalaemia 188	52–3	impairment 188–9
acute myocardial infarction, sick	levels in congenital adrenal	amiodarone 21–2
euthyroid syndrome 16, 19, 20	hyperplasia 69	effects on thyroid function 23-4,
Addison's disease 50, 160	adrenocorticotrophic hormone	25–6
antibodies 110	(ACTH) deficiency	surveillance of patients 22
autoimmune polyglandular	clinical features 91	use after cardiac surgery 24
syndromes 55	glucocorticoid replacement 207	use in thyrotoxic crisis 40
replacement therapy 205-9	agranulocytosis, as side effect of	amiodarone-induced
adipose tissue, increase in thyroid	thionamide drugs 2, 8–9, 210,	thyrotoxicosis, management
eye disease 46–7	211,212	24, 25
adrenal carcinoma 59-60	AIDS/HIV	anabolic steroids, use in delayed
hypertension 167	gynaecomastia 140	puberty 134
adrenal crisis	hypogonadism 126	anagen 113
management 52	AIRE gene 55,56	anaplastic thyroid cancer 13
risk factors for 53	albumin, serum levels 18	anastrozole
adrenal function, assessment in	alcohol consumption, in	use in ovulation induction 107
premature ovarian failure 111	hypertension 164,168	value in gynaecomastia 140
adrenal glands	alcoholism	androgen dependence, hair
adenoma, Conn's syndrome 167	hypocalcaemia 159, 160	differentiation 113
congenital hyperplasia 68–73	hyponatraemia 180	androgen levels in PCOS 100
incidental nodules 59, 177	aldosterone 50, 174, 179	androgen receptor gene, (CAG)n
differential diagnosis 59-60	see also hyperaldosteronism	repeat polymorphism 149
investigation 60-1	aldosterone antagonists 177	androgen replacement therapy
management 61–2	see also spironolactone	available preparations 129
nodules, as cause of Cushing's	aldosterone levels, relationship to	in delayed puberty 134
syndrome 67	hypertension 177	in erectile dysfunction 123-4
reduced androgen production 117	aldosterone-producing adenoma	in hypoadrenalism 209
tumours, as cause of	(APA) 174, 175, 177	in hypopituitarism 92
gynaecomastia 136, 138	aldosterone to renin ratio (ARR)	in Klinefelter's syndrome
adrenal insufficiency 49–50, 53–4	167, 175–7, 178	149, 150
differential diagnosis 51,53	alfacalcidol 221,222	in male hypogonadism 127–8
genetic syndromes 50, 52	alkalosis, effect on potassium levels	in women 129, 224, 225, 227
replacement therapy 205-9	185	in premature ovarian failure 111
symptoms 52	Allgrove's (triple A) syndrome 52	in prolactinoma 130
adrenalectomy, in congenital	alpha-blockade, in	androgens, high levels, differential
adrenal hyperplasia 72	phaeochromocytoma 171	diagnosis 116



angiotensin-converting enzyme (ACE) inhibitors interference with ARR 177 in treatment of hypertension 164 angiotensin receptor blockers 164 anorexia nervosa 97-8 anovulatory infertility, causes 104 anti-androgen drugs 117-18 use in congenital adrenal hyperplasia 72 anti-Fp antibodies 44 anti-G2s antibodies 44 antiarrhythmic drugs new agents 24 see also amiodarone antibodies in Addison's disease 50,52 in autoimmune polygiandular syndromes 56 antidiuretic hormone (ADH, arginine vasopressin) 179, 194-5 AVP receptor blockers 184 nocturnal secretion 198 SIADH 181, 183, 184 antineutrophil cytoplasmic antibodies (ANCAs) 211,

212 - 13antipsychotic drugs, as cause of hyperprolactinaemia 82-3 antithyroid peroxidase (anti-TPO) 35,38

apathetic thyrotoxicosis 39 apathy, in hypopituitarism 92 APECED (autoimmune polyendocrinopathy-

candidiasis-ectodermal dystrophy) 55,56 apomorphine, use in erectile

dysfunction 121 aquaporins 195,216

AQP2 gene mutations 196 arginine vasopressin (AVP) 179, 194-5, 197

AVP receptor blockers 184 nocturnal secretion 198 see also antidiuretic hormone aromatase inhibitors

in congenital adrenal hyperplasia

use in delayed puberty 134 use in Klinefelter's syndrome 150 use in ovulation induction 107 AroQol questionnaire 78 arrhythmias, in hypokalaemia 186

Asherman's syndrome 100

atenolol, in treatment of hypertension 164 athletes, female athlete triad 97

asthma, nebulized magnesium

atrial fibrillation in hyperthyroidism 7

sulphate 193

management 24,25 atrial natriuretic peptide levels, in

Addison's disease 206 autoimmune disease

association with miscarriage 30,33 role of microchimerism 37

autoimmune polyendocrinopathy syndrome 158, 162

autoimmune polyglandular syndromes 54-5, 57-8 investigation 56

monitoring and follow-up 57 autoimmune thyroid disease 7

autoimmune polyglandular syndromes 55

genetic factors 3 post-partum thyroid disturbance

35-8 see also Graves' disease

autoimmunity, role in premature ovarian failure 109-10 AVP receptor blockers 184

azathioprine, use in thyroid eye disease 46

azoospermia, semen fructose levels 126

В ballet dancers, menstrual disorders

Bartter-like syndrome, after gentamicin treatment 188-9

Bartter's syndrome 187 basal metabolic rate (BMR) during pregnancy 33-4

basophil pituitary adenoma 66 bazedoxifene 225 bepridil 24

beta-blockers

interference with ARR 176 use in hypertension 164 use in phaeochromocytoma 171 use in post-partum thyroid

disturbance 35 use in thyrotoxic crisis 40

bicalutamide 118 big prolactin 83-4

bilateral adrenal hyperplasia (BAH) 174, 175, 177

biopsy

goitre 7

testicular 126, 149, 150

bipolar illness 214-15 see also lithium

bisphosphonates, use in

hyperparathyroidism 156 block and replace regimens, thyrotoxicosis 2-3

blood pressure

diurnal variation 168

see also hypertension

body mass, as trigger to puberty

bone age assessment 133

bone mineral density (BMD) effect of growth hormone

replacement 94

effect of hyperthyroidism 7-8

botulinum toxin, use in thyroid eye disease 46

breast cancer

androgens as risk factor 129 male 140

risk from HRT 224, 225

risk in Klinefelter's syndrome 150

risk in PCOS 101 breastfeeding, and amiodarone 22

bromocriptine, in treatment of prolactinoma 82

bulimia nervosa 98 buserelin 117

C-reactive protein, levels in subclinical hypothyroidism 30 cabergoline

use in acromegaly 78

use in non-functioning pituitary adenoma 87

use in prolactinoma 82,84 calcitriol 221,222

calcium 158

plasma level measurement 153 see also hypercalcaemia;

hypocalcaemia

calcium channel blockers interference with ARR 177

use in hypertension 164

use in phaeochromocytoma 171 calcium-sensing receptor 156

calcium-sensing receptor gene abnormalities 161

calcium supplementation 160, 221, 222 - 3

in premature ovarian failure 111

cancer	cavernous sinus, pressure effects	congenital adrenal hyperplasia
of adrenal glands 59–60	from pituitary adenoma 86	(CAH) 68–9,70,72–3
risk in acromegaly 76	cavernous sinus sampling 66	biochemical changes 69
risk in Klinefelter's syndrome	cetrorelix 107,117	21-hydroxylase deficiency 69–70
150	chemotherapy, protection of	hypertension 167
of thyroid 7	ovaries 111	non-classic 21-hydroxylase
and amiodarone 23	chlorpropamide, use in diabetes	deficiency 70-2
fine needle aspiration	insipidus 197	congenital adrenal hypoplasia 53
cytology (FNAC) 11–12	cholecalciferol (vitamin D ₃) 219,	congenital pituitary failure 91
management 13, 15	221	conivaptan 183
papillary 12, 14	cholestyramine, use in thyrotoxic	Conn's syndrome 59, 60, 167, 168,
post-partum thyroid	crisis 41	174–5,178
disturbance as risk factor	chondrocalcinosis 154	investigation 175-7
37	chromogranin 170	management 177
see also breast cancer;	levels in phaeochromocytoma	constitutional delayed puberty,
endometrial cancer	62	management 134
candidiasis, in APECED 55	Chvostek's sign 160	contraception
canrenone 177	ciclosporin	perimenopausal 224
captopril isotope renogram 165	interaction with amiodarone 22	in premature ovarian failure
captopril suppression test 175	use in thyroid eye disease 46	110,111
carbamazepine, use in diabetes	cimetidine, use in hirsutism 118	convulsions, in hypocalcaemia
insipidus 197	cinacalcet 156	159
carbimazole (CBZ) 2,4	cisapride, stimulation of cortisol	corrected total calcium 158
in amiodarone-induced	production 62	corticosteroids see steroids
thyrotoxicosis 24	clomiphene citrate 105, 106	corticotrophin-releasing hormone
fatal adverse reactions 211	value in gynaecomastia 140	(CRH), levels in congenital
neutropenia 210, 213	clomiphene stimulation test, in	adrenal hyperplasia 69
use during pregnancy 33	male hypogonadism 126	corticotrophin-releasing hormone
use in thyroid eye disease 47	clonidine	test 64,65–6
use in thyrotoxic crisis 40	interference with ARR 176	cortisol 50,207
cardiac abnormalities, in Turner's	in treatment of menopausal	levels in Conn's syndrome 175
syndrome 143	symptoms 224	cortisol production, measurement
cardiac arrest, use of vasopressin	clonidine suppression test 170	60
197	coeliac disease	cortisone, potency 206
cardiac failure	in autoimmune polyglandular	counselling, in Klinefelter's
during pregnancy 33	syndromes 55,57	syndrome 149
T ₃ as prognostic factor 19	as cause of short stature 133	cranial diabetes insipidus 195, 197,
cardiovascular disease risk	in Turner's syndrome 143	199
in acromegaly 76	colestipol, use in thyrotoxic crisis 41	CTLA-4 gene 55
in hypokalaemia 188	colon cancer, risk in acromegaly 76,	Cushing's syndrome 59,60,62,67
in Klinefelter's syndrome 147, 150	79	clinical features 64
in PCOS 101	colour Doppler sonography, in	differential diagnosis 64
in primary hyperparathyroidism	diagnosis of thyroid disorders	hypertension 165
156	5,23	investigation 63-4, 64-6
Carney complex 67,75	combined oral contraceptive, in	treatment 66
L-carnitine, use in thyrotoxic crisis	management of PCOS 101-2,	cyclophosphamide, use in thyroid
42	107,117	eye disease 46
Carpenter's syndrome 55	combined thyroid hormone	CVPLIA considerate 70
carpopedal spasm 159	replacement 228–9, 230, 231	CYP11A gene defects 70
catagen 113 catecholamines	complications of surgery	CYP11B1 gene defects 70
	for pituitary adenomas 85–6	CYP11B2 gene polymorphisms 178
effect on potassium levels 185	thyroidectomy 9	CYP17 gene polymorphisms 70
plasma levels 170	computed tomography in acromegaly 76	cyproterone 225
secretion in congenital adrenal hyperplasia 72	incidental adrenal tumours 59,	use in hirsutism 117
urinary 60	60	CYR61 gene 47
dillary 00	OV.	Strot gene 47



cytokines	Carpenter's syndrome 55	duration of treatment,
effect on deiodinase enzymes 19	type 2	thyrotoxicosis 2
role in vitamin D production	in PCOS 101, 102	dydrogesterone 225
219	potassium channel disorders	dyslipidaemia, in subclinical
cytotoxic T lymphocyte antigen-4	188	hypothyroidism 29-30
(CTLA-4) 3	in Turner's syndrome 145	dystrophia myotonica 127
(512217)	diabetes insipidus 195-6, 199	ayou op ma my out mea 12)
D	after surgery for pituitary	E
dantrolene, use in thyrotoxic crisis	adenoma 86	early gestational thyrotoxicosis 33
42		
*	as complication of head injury	eating disorders
DAX-1 gene 50,53	93, 195, 197–8	association with amenorrhoea
DDAVP (1-desamino-8-D-arginine	investigation 196-7, 198	97-8
vasopressin) 197,199	lithium-induced 216–17	electrolyte abnormalities 186
defibrillators, implantable 25	treatment 92, 197	ECG
dehydroepiandrosterone 50,53	dialysis, use in thyrotoxic crisis 42	changes in hypokalaemia 186
elevated levels 114	diazoxide, use in insulinoma 201	changes in hypomagnesaemia
dehydroepiandrosterone therapy	DIDMOAD (Wolfram's syndrome)	192
in Addison's disease 209	195	ectopic ACTH secretion 64,65
in post-menopausal women	digoxin, interaction with	eflornithine (Vaniqa) 116
129,227	amiodarone 22	elderly people
deiodinase (DI) enzymes 18, 19	dihydrotachysterol 221,222	hyponatraemia 180
effect of amiodarone 23	dihydrotestosterone 129	nocturia 198
delayed puberty 131, 135	dipsogenic polydipsia 196	thyroid hormone replacement
causes 132	DIPTA (3,5-diiodothyropropanoic	therapy 229,231
investigation 132–4	acid) 19	embolism, risk in hyperthyroidism 7
management 134	diuretic therapy	endocrine-related hypertension
demeclocycline, use in		164–5
hyponatraemia 183	hypokalaemia 189	differential diagnosis 166
deoxycorticosterone (DOC) 167	hyponatraemia 183 diuretics, interference with ARR	endometrial cancer
		risk from HRT 224
in congenital adrenal hyperplasia 70	177	_
	diurnal variation in blood pressure	risk in PCOS 101
depilatory creams 116	168	endothelial dysfunction, role in
depression, association with post-	domperidone, response in	erectile dysfunction 122
partum thyroid disease 37	prolactinoma 81-2	EPHESUS (Eplerenone
desmopressin, in management of	dopamine, secretion by	Neurohormonal Efficacy and
hypopituitarism 92	phaeochromocytoma 167,	Survival Study) 177
desmopressin test 66	170, 171	epilation techniques 116
developmental delay, in Klinefelter's	dopamine agonists	eplerenone 177
syndrome 147	effect on headache in pituitary	erectile dysfunction 119
dexamethasone	adenoma 85	causes 120
potency 206	use in acromegaly 76,78	investigation 120, 124
use in hirsutism 117	use in hypopituitarism 92	management 120-4
use in non-classic congenital	use in non-functioning pituitary	in prolactinoma 81
adrenal hyperplasia 72	adenoma 87	erection, mechanism 119, 121
use in thyrotoxic crisis 40	use in prolactinoma 81,82,84	ergocalciferol (vitamin D ₂) 219,
dexamethasone suppression test	dopamine antagonists test,	221,222
(DST) 64	prolactinoma 81–2	ethanol ablation of thyroid nodules
dextrose	doxazocin, use in	9
use in acute hypoglycaemia 203	phaeochromocytoma 171	ethinyloestradiol, use in delayed
use in adrenal crisis 52		puberty 134, 145
diabetes	DQB1 gene 56 dronedarone 24	etomidate therapy, Cushing's
		disease 66
erectile dysfunction 120	drospirenone 118	exercise
in Klinefelter's syndrome 149	drug-induced gynaecomastia 138	
type 1	drug interactions, with amiodarone	as cause of hyperkalaemia 185
association with menstrual	22	hormonal response in congenital
and fertility disorders 98	dumping syndrome 203	adrenal hyperplasia 72

exophthalmos see thyroid eye	Framingham Offspring Study,	gonadarche 132
disease	aldosterone levels and	gonadotropin deficiency, clinical
eyes, side effects of amiodarone 22	hypertension 177	features 91
F	free androgen index (FAI) 114, 125	gonadotropin levels in acromegaly 76
factitious hypoglycaemia 201	fructose, semen levels 126	in Klinefelter's syndrome 148,
familial benign hypocalciuric	functional adrenal imaging 60-1	149
hypercalcaemia 161	8 8	in male hypogonadism 125–6
familial glucocorticoid deficiency 52	G	in premature ovarian failure 111
familial hyperaldosteronism (FH)	galactorrhoea 81	gonadotropin-releasing hormone
syndromes 177–8 familial periodic paralysis 186	gamma interferon, role in vitamin	(GnRH) agonist test 134
fasting hypoglycaemia 200, 201	D production 219 gamma knife	gonadotropin-releasing hormone (GnRH) agonists and
female athlete triad 97	for non-functioning pituitary	antagonists, use in hirsutism 117
feminising adrenal tumours 60	adenoma 87	gonadotropin-releasing hormone
Ferriman-Gallwey score 113-14	use in acromegaly 76	(GnRH) test
fertile eunuch syndrome 126	ganirelix 107,117	in delayed puberty 134
fertility	gastric bypass surgery,	in male hypogonadism 126
in congenital adrenal hyperplasia 73	hypoglycaemia 203	gonadotropin-releasing hormone
effect of subclinical	GATA3 gene mutation 160 genetic counselling, in Klinefelter's	(GnRH) therapy, pulsatile 106–7
hypothyroidism 28	syndrome 149,150	gonadotropin therapy, ovulation
in premature ovarian failure 111	genetic factors	induction 105–7
reduction in prolactinoma 81	in Grave's disease 3,5	goserelin 117
see also infertility	in premature ovarian failure 109	grapefruit juice, effect in
finasteride 117, 118	genital abnormalities, congenital	amiodarone therapy 23
fine needle aspiration cytology (FNAC), thyroid nodules	adrenal hyperplasia 69, 70 genotyping, value in autoimmune	Graves' disease 1-2,6,37
11–12, 15	polyglandular syndromes 56,57	antineutrophil cytoplasmic antibodies 213
diagnostic categories 13	gestational diabetes insipidus 196,	colour Doppler sonography 5
fludrocortisone	197	genetics 3
potency 206	Gitelman's syndrome 180, 187	investigations 5
replacement therapy in Addison's	glitazones see thiazolidinediones	neutropenia 210
disease 205-6, 208, 209	glucagon-like peptide (GLP)-1, as	post-partum incidence 35
use in adrenal crisis 52 fludrocortisone suppression test 175	cause of hypoglycaemia 201, 203	during pregnancy 33 risk factors 3,5
fluid restriction, in hyponatraemia	glucocorticoid-remediable	thionamide drug treatment 2-3,
183	aldosteronism 168	4
fluid resuscitation, in adrenal crisis	glucocorticoid replacement therapy	thyroid eye disease 43-7
52	in Addison's disease 206-8, 209	thyrotoxic crisis 39-42
flutamide, use in hirsutism 117	in hypopituitarism 91–2	growth hormone deficiency, clinical
follicle-stimulating hormone (FSH)	glucocorticoids see steroids	features 91
in diagnosis of menopause 224 levels in Klinefelter's syndrome	glucose intolerance in PCOS 101	growth hormone levels, in acromegaly 76, 78
148, 149	in Turner's syndrome 145	growth hormone stimulation tests
levels in male hypogonadism	glucose tolerance test, in diagnosis	134
125	of acromegaly 76,79	growth hormone therapy 94
levels in premature ovarian	goitre	in hypopituitarism 92
failure 111	differential diagnosis 6–7	in Turner's syndrome 145, 146
use in male hypogonadism 128	estimation of size 9	gynaecomastia 136
use in ovulation induction 105–6	investigation 7,8 in lithium therapy 217	differential diagnosis 136–8 drug-induced 138
follicular thyroid cancer,	radioactive iodine treatment 9,	investigation 139–40
management 13	10	in Klinefelter's syndrome 149
follow-up, after treatment of	surgical treatment 9-10	risk of malignancy 140
thyrotoxicosis 10,42	thionamide treatment 8–9	treatment 140,141



H	HLA-DR3, as marker for Grave's	Conn's syndrome 174–8
haemochromatosis 127	disease 3	mineralocorticoid
haemodialysis, use in thyrotoxic	hydrochlorothiazide, action in	hypertension 167-8
crisis 42	diabetes insipidus 198	phaeochromocytoma 167,
haemophilia, use of vasopressin	hydrocortisone	169–73
197	potency 206	investigation 164,165,168
hair growth, phases 113	replacement therapy in Addison's	secondary, causes 164
Hashimoto's thyroiditis 6	disease 53-4, 206, 207-8, 209	treatment 164
HDR syndrome 160	use in adrenal crisis 52	in Turner's syndrome 143
head injury	use in congenital adrenal	hyperthyroidism
diabetes insipidus 195, 197–8,	hyperplasia 70	during pregnancy 32-3, 34
199	1α-hydroxylase 219, 220	Graves' disease 1-5
hypopituitarism as complication	17β-hydroxylase deficiency 70	multinodular goitre 6, 7–10
93,94	21-hydroxylase deficiency 68,	see also thyrotoxicosis
headache, in pituitary adenoma 85	69–70	hypertonic saline 183
heart disease, use of PDE-5	neonatal screening 72	in investigation of diabetes
inhibitors 122	non-classic 70-2,73	insipidus 197
heart failure, hyponatraemia 183-4	17-hydroxyprogesterone, in	hypertrichosis 113
hepatotoxicity, thionamide drugs	congenital adrenal hyperplasia	hypocalcaemia
211–12	69	after thyroidectomy 219, 222–3
high androgen states, differential	3β-hydroxysteroid dehydrogenase	causes 158-9
diagnosis 116	deficiency 70	clinical features 159-60
high-dose dexamethasone	11β-hydroxysteroid dehydrogenase	investigation and management
suppression test 64	deficiency 70, 168	160–2
hirsutism 113–14	hyperaldosteronism 59,60,167,	hypoglycaemia 200, 203
drug treatments 117-18	168, 174–5, 178	investigation 200-1,202
investigation 114,115	familial hyperaldosteronism	management 201
local and topical treatments	(FH) syndromes 177–8	in polycystic ovarian syndrome
115–16	investigation 175-7	201,203
HIV/AIDS	management 177	hypogonadism
gynaecomastia 140	hypercalcaemia	in acromegaly 76
hypogonadism 140	causes 154	male 125–30
homocysteine, raised levels in	differential diagnosis 155	gynaecomastia 137, 138
polycystic ovarian syndrome	investigation 153-4	Klinefelter's syndrome
72	in lithium therapy 217	147–50
hook effect, prolactin assays 81	hyperemesis gravidarum 32–3, 34	hypogonadotropic hypogonadism
hormone replacement therapy	hyperglycaemia, in	50, 126-8
(HRT) 224–5,227	phaeochromocytoma 170	hypokalaemia 175, 185, 188–9
scheme for initiation 226	hypergonadotrophic	causes 1868
Horner's syndrome 7	hypogonadism	symptoms 186
HSD3B1 gene defects 70	differential diagnosis 127	treatment 188
human chorionic gonadotropin (hCG)	Klinefelter's syndrome 147–50 hyperkalaemia	hypomagnesaemia 158–9, 160, 190
response in Klinefelter's	in adrenal crisis 52	causes 191 clinical features 192
· .		
syndrome 149	after exercise 185 hyperparathyroidism, primary	management 191, 193 hyponatraemia
similarity to TSH 31,32 use in male hypogonadism 128	154–7	causes 180, 181, 183
use in ovulation induction 105,	in lithium therapy 217	clinical features 180
106	hyperprolactinaemia 80,105	in eating disorders 186
human chorionic gonadotropin	differential diagnosis 81	in heart failure 183–4
stimulation test in delayed puberty 134	drug-induced 82–3 see also prolactinoma	management 182, 183, 184 in marathon participants 184
in male hypogonadism 126	hypertension 163	hypoparathyroidism 158, 160, 162
human leucocyte antigen (HLA)	adrenal tumours 60	after thyroidectomy 9,219,223
complex 3	association with PCOS 101	vitamin D supplementation
associations with APS II 55	endocrine causes 164–6	222

hypopituitarism 94	impotence see erectile dysfunction	iopanoic acid, use in thyrotoxic
causes 90	incidentalomas, adrenal 59–62	crisis 41
clinical features 91	¹¹¹ Indium-labelled octreotide, use	ipodate, use in thyrotoxic crisis
in Cushing's syndrome 67	in imaging in acromegaly	41
after head injury 93	76	IQ, effect of maternal
investigations 91,92	inferior petrosal sinus sampling	hypothyroidism 29
management 91-2,93	(IPSS) 66,67	iron supplements, value in delayed
risk factors for 91	infertility	puberty 134
risk in prolactinoma 82	causes 104	
secondary adrenal failure 49–50	hCG therapy in male	К
hypothalamus, pressure effects	hypogonadism 128	Kallman's syndrome 126, 130, 137
from pituitary adenoma 86	in Klinefelter's syndrome 149,	Kearns-Sayre syndrome 52
hypothyroidism	150	ketoconazole 117
in acromegaly 76	management in PCOS 105-8	use in Cushing's disease 66
amiodarone-induced 23	in Turner's syndrome 142, 145,	ketones, in fasting hypoglycaemia 201
hypertension 165	146	kidneys
hyponatraemia 183	see also fertility	abnormalities in Turner's
in lithium therapy 217,218	inflammatory bowel disease, in	syndrome 143
in post-partum thyroid	Turner's syndrome 143	effects of lithium 215-17
disturbance 35-6, 37, 38	influenza immunization, in	potassium regulation 185
during pregnancy 33,37	acromegaly 79	tubular disorders 187-8
subclinical 27–30	inositol monophosphate, inhibition	sodium regulation 180
thyroid hormone replacement	by lithium 217	Klinefelter's syndrome 125
228–31	insulin, effect on potassium levels	breast cancer risk 140
in Turner's syndrome 145	185	clinical features 147
	insulin levels, in subclinical	investigation and management
1	hypothyroidism 30	148–50
131 I treatment 10	insulin-like growth factor (IGF)-I	
in amiodarone-induced	in acromegaly 76,78,79	L
thyrotoxicosis 23,24	in delayed puberty 133	lanreotide
in thyroid cancer 13	insulin-like growth factor (IGF)-II,	in treatment of acromegaly
after thyrotoxic crisis 42	as marker for malignant	78
in thyrotoxicosis 3,5,8,9	adrenal masses 62	use in insulinoma 201
worsening of thyrotoxicosis 40,42	insulin resistance	laparoscopic ovarian drilling (LOD)
ibutilide 24	in adrenal disorders 72	107
idiopathic hirsutism 114	association with hirsutism	laparoscopic surgery, for adrenal
illness	118	nodules 61-2
adjustment of steroid therapy	in PCOS 100, 102	laser coagulation, thyroid lesions 15
206	relationship to magnesium status	laser treatment of hirsutism 116
management in adrenal	193	Laurence-Moon-Bardet-Biedl
insufficiency 53-4	in Turner's syndrome 145	syndrome 126
IMAGe syndrome 52	insulin sensitivity, role of	learning difficulties, in Klinefelter's
imaging	testosterone 130	syndrome 147
in acromegaly 76	insulinoma 201	leptin 34,98
of adrenal tumours 60–1	intracavernosal injection, in	letrozole, use in ovulation
	treatment of erectile	induction 107
in Conn's syndrome 177		leuprolide 117
in Cushing's syndrome 66	dysfunction 121	levonorgestrel 225
in hyperparathyroidism 156	intracytoplasmic sperm injection	Leydig cell tumours 136
of insulinoma 201	(ICSI) 149,150	LH/FSH ratio in PCOS 100
of phaeochromocytoma 167,	intrauterine diagnosis, congenital	Liddle's syndrome 168, 187
170–1	adrenal hyperplasia 70	lifestyle modification, in
in prolactinoma 82	iodine	management of PCOS 101,
in renal artery stenosis 165	as constituent of amiodarone	102, 103
of thyroid eye disease 44,47	23	light sensitivity, effect of
immunosuppression, use in thyroid	use in thyrotoxic crisis 40	amiodarone 22
eye disease 46	ionized calcium 158	WILLIO WILLOWS WAR



linear accelerator, use in acromegaly	malabsorption, vitamin D	"C metomidate 61
76	supplementation 222	metoprolol, use in
lithium	male hypogonadism 125	phaeochromocytoma 171
mechanism of action 217	hypergonadotrophic	metyrapone test 66
side effects and toxic effects 215	hypogonadism 127	metyrapone therapy, Cushing's
effects on thyroid 217, 218	hypogonadotropic	disease 66
hypercalcaemia 217	hypogonadism 126–8	MIBG (metaiodobenzylguandine)
nephrogenic diabetes	investigation 125-6	60, 171
insipidus 196, 198, 216–17	malignancy	microchimerism, role in
renal toxicity 215-16	risk in phaeochromocytoma 171	autoimmune disease after
use in hyponatraemia 183	see also cancer	pregnancy 37
use in thyrotoxic crisis 40,42	marathon participants,	microprolactinoma 80
lithium therapy, care pathway 216	hyponatraemia 184	treatment 82
liver, side effects of amiodarone 22	Massachusetts Male Aging Study	see also prolactinoma
liver disease	(MMAS) 119	mineralocorticoid hypertension
gynaecomastia 136	mastectomy, for gynaecomastia	167–8
vitamin D supplementation 222	140	mineralocorticoid receptor
liver enzyme abnormalities,	MCT8 mutations 19	mutation 167
thionamide drugs as cause 211	medroxyprogesterone 225	mineralocorticoid replacement,
long Synacthen test 53	medullary carcinoma of thyroid 13	Addison's disease 205-6,
loop diuretics 180	menopause 223–4	208-9
low-density lipoprotein (LDL)	see also hormone replacement	mineralocorticoid status,
cholesterol, effect of	therapy (HRT)	investigation 53
subclinical hypothyroidism	menstrual cycle, effect of subclinical	minimally invasive surgery, thyroid
29-30	hypothyroidism 28	lesions 10
lung cancer, risk in Klinefelter's	metabolic syndrome	minimally invasive video-assisted
syndrome 150	association with SAGH 62	thyroidectomy (MIVAT) 10
luteinising hormone (LH)	in PCOS 102, 107	miscarriage, association with
levels in Klinefelter's syndrome	relationship to magnesium status	autoimmune disease 30,33
148, 149	193	mitotane therapy, Cushing's disease
levels in male hypogonadism	metaiodobenzylguanidine	66
125-6	60, 171	mood disturbance in
lymphoedema, in Turner's	metanephrines, urinary 60, 170	hypothyroidism 229
syndrome 142	metastases, adrenal 59	MORE (Multiple Outcomes of
lymphoma, risk in Klinefelter's	metformin	Raloxifene Evaluation) trial
syndrome 150	in management of PCOS 102,	225
lymphoma of thyroid 13	107, 117	mosaicism
, 1	use in ovulation induction	in Klinefelter's syndrome 147,
M	105, 106	149
McCune-Albright syndrome 67, 75	in treatment of congenital	in Turner's syndrome 142, 143,
macroprolactin 83	adrenal hyperplasia 72	145
magnesium 190	methimazole (MMI) 2, 4, 8	multinodular goitre, radioactive
competition with lithium 215	in amiodarone-induced	iodine treatment 9
<i>see also</i> hypomagnesaemia	thyrotoxicosis 24	multiple endocrine neoplasia
magnesium balance 191, 192	side effects 210	(MEN)
magnesium sulphate	methyldopa, interference with ARR	hyperparathyroidism 154
use in asthma 193	176	phaeochromocytoma 167,170
use in pre-eclampsia 193	methylphenidate, use in	type I 67,75
magnesium supplementation 160,	hypopituitarism 92	mumps orchitis 127
191, 193, 222–3	methylprednisolone	muscle activity, effect on potassiun
magnetic resonance imaging	potency 206	levels 185
in acromegaly 76	use in thyroid eye disease 46,47	muscle symptoms, in thyrotoxic
in Cushing's syndrome 66	methyltestosterone therapy, in post-	crisis 39
phaeochromocytoma 60, 170-1	menopausal women 129	muscle weakness, in hypokalaemia
in prolactinoma 82	metoclopramide, response in	186
in thyroid eye disease 44,47	prolactinoma 81–2	myelolipoma 60
	PIVIDGERIQUE UI'''4	2117 CIOUPOUM OU

N	nutritional supplements, value in	PADAM (partial androgen
N-terminal pro-B-type natriuretic	delayed puberty 134	deficiency in ageing men)
peptide, in	delayed paterty 157	127, 128, 130
hyperparathyroidism 156	0	papaverine, intracavernosal
neonatal hyperthyroidism 33	obesity, as risk factor for Graves'	injection 121
nephrogenic diabetes insipidus	disease 5	papillary thyroid cancer 12
196, 197	obstructive symptoms, goitre 7	management 13
lithium-induced 216-17	octreotide	multifocal 15
nesidioblastosis 203	use in acromegaly 78	prognosis 14
Nestorone 225	use in insulinoma 201	paracalcitol 221
neurodegenerative disease,	use in thyroid eye discase 47	paraganglionomas 171-2
association with transthyretin	oestrogen, use in delayed puberty	parathyroid glands
18	134, 145	changes in lithium therapy 217,
neurofibromatosis,	oestrogen deficiency, symptoms	218
phaeochromocytoma 170	224	damage during thyroidectomy
neuropathy, as side effect of	oestrogen levels in PCOS 100, 101	162
amiodarone 22	oestrogen replacement	primary hyperparathyroidism
neutropaenia, as side effect of	HRT 224-5,226	154–7
thionamide drugs 2,8-9,210,	in hypopituitarism 92	parathyroid hormone, controlled
211,212,213	in premature ovarian failure	release therapy 162
NHANES (National Health and	111, 112	parathyroid hormone levels, role of
Nutrition Examination	17-OHP, in congenital adrenal hyperplasia 71, 72	vitamin D status 222
Survey) II, hypothyroidism 27	ondansetron, use in hyperemesis	parathyroidectomy 156
nilutamide 118	gravidarum 32	paroxetine, in treatment of
nipples, in Turner's syndrome 142 nocturia 198	oocytes, differentiation from stem	menopausal symptoms 224 peak systolic velocity (PSV), in
non-arteritic anterior ischaemic	cells 111	erectile dysfunction 120
optic neuropathy (NAION)	oral glucose tolerance test, in	pegvisomant, in treatment of
122–3	diagnosis of acromegaly 76,79	acromegaly 78
non-classic 21-hydroxylase	orbital decompression 46	Pemberton's manoeuvre 7
deficiency 70–2,73	orlistat, use in PCOS 105	penile duplex ultrasonography
non-functioning pituitary	osmotic demyelination syndrome	120
adenomas 85	183	penile implants 121
management 85-8	osteoporosis 222	peptic ulceration, in primary
pressure effects 86	dietary risk factors 188	hyperparathyroidism 154
non-steroidal anti-inflammatory	in hypogonadism 125	peptides, secretion by
drugs	prevention in premature ovarian	phaeochromocytoma 167
interference with ARR 176	failure 111	perchlorate, in amiodarone-
value in lithium-induced	risk in hyperthyroidism 7–8	induced thyrotoxicosis 24
diabetes insipidus 217	ovarian androgen production,	peritoneal dialysis, use in thyrotoxic
noradrenaline	inhibition 117	crisis 42
effect on potassium levels 185	ovarian cancer, risk in PCOS 101	peroxisome proliferator-activated
secretion in congenital adrenal	ovarian failure	receptor (PPAR)-y agonists, in
hyperplasia 72	in Turner's syndrome 142	treatment of Cushing's disease
secretion by	see also premature ovarian failure	67
phaeochromocytoma 167, 170	ovarian hyperthecosis 114 ovarian tissue, cryopreservation	pesticides, effect on thyroid
norethisterone 225	111	hormone levels 29
norgestrel 225	ovarian transplantation, in Turner's	pH, effect on potassium levels 185
NOSPECS classification, thyroid eye disease 44	syndrome 145	phaeochromocytoma 60,62,167,
NP-59 (131I-6-beta-	ovarian wedge technique 107	168, 169–70
iodomethylnorcholesterol)	ovulation induction in PCOS 105–7	clinical features 170
scanning 60–1, 177		investigation and treatment
Nurses' Health Study	Р	170–1, 172–3
Grave's disease 3,5	p53 mutations 62	phenoxybenzamine, use in
magnesium status 193	P450 _{sqc} deficiency 70	phaeochromocytoma 171



phosphodiesterase-5 (PDE-5) pre-eclampsia, use of magnesium primary polydipsia 196 sulphate 193 inhibitors 120-1 progesterone, in management of comparison of agents 122 PCOS 102 pre-natal treatment, congenital and non-arteritic anterior adrenal hyperplasia 70 progestin challenge test 111 ischaemic optic neuropathy prednisolone progestogen-only HRT 224 progestogens, in HRT 224, 225, 226 potency 206 (NAION) 122-3 pituitary adenomas 66 use in hirsutism 117 prolactin isoforms 83-4 prolactin levels non-functioning 85-8 use in non-classic congenital prolactinoma 80-4 adrenal hyperplasia 72 in acromegaly 76 use in thyroid eye disease 46, 47 silent corticotroph adenomas in hypopituitarism 91 (SCAs) 66~7 in male hypogonadism 126 pregnancy somatotroph adenomas 75,76 and amiodarone 22 prolactin receptor antagonists 84 pituitary apoplexy 85, 87, 91 autoimmune polyglandular prolactinoma 80-1,126 pituitary failure see hypopituitarism syndromes 57-8 androgen replacement therapy plasma exchange, use in thyrotoxic basal metabolic rate 33-4 130 crisis 42 congenital adrenal hyperplasia, investigation 81-2 management 82,83,84 plasmapheresis, use in thyrotoxic management 72 diabetes insipidus 196, 197 crisis 42 prolonged dexamethasone pneumococcal vaccination, in exacerbation of hypertension suppression test (DST) 64 acromegaly 79 167 prolonged glucose tolerance test polychlorinated biphenyls, effect on hyperemesis gravidarum 32-3, 201,203 propranolol, use in thyrotoxic crisis thyroid hormone levels 29 polycystic ovarian syndrome and hypocalcaemia 162 (PCOS) 100-3 hypothyroidism 28-9 propylthiouracil (PTU) 2, 4, 9 as cause of subfertility 104-8 and prolactinoma 82 side effects 211, 212-13 screening for thyroid disease 37 in congenital adrenal hyperplasia use in thyrotoxic crisis 40 thyroid function 31-2 see also thionamide drugs hirsutism 114,117,118 thyrotoxicosis 33,34 prostate cancer, risk in Klinefelter's hypoglycaemia 201, 203 premature death, risk in syndrome 150 polydipsia 196 Klinefelter's syndrome proton beam radiotherapy, use in 149-50 see also diabetes insipidus acromegaly 76 polyuria see diabetes insipidus premature ovarian failure (POF) pseudohyponatraemia 180-1 portal hypertension 197 108-9,112 puberty 131-2 positron emission tomography causes 109-10 age at onset 134 adrenal masses 62 investigation and management delayed 131,135 phaeochromocytoma 171 110,111 causes 132 post-menopausal women pressure effects, non-functioning investigation 132-4 androgen therapy 129, 225, 227 pituitary adenomas 86 management 134 see also hormone replacement priapism, as side effect of alprostadil gynaecomastia 136,140 therapy 121 induction in Turner's syndrome post-partum thyroid disturbance primary amenorrhoea 95 145, 146 33, 35-8 assessment 96-8 pulmonary fibrosis 22 potassium balance 185-6 causes 96 see also hypokalaemia premature ovarian failure 109, potassium canrenoate 177 112 quality of life, in acromegaly 78 potassium channel disorders primary hyperaldosteronism 59, 188 60, 167, 168, 174, 175, 178 potassium iodide, use in thyrotoxic investigation 175-7 R139X mutation 55 crisis 40 primary hyperparathyroidism R257X mutation 55 potassium levels, in Conn's radioactive iodine treatment 10 clinical features 154 syndrome 167 differential diagnosis 155 after thyrotoxic crisis 42 potassium supplementation 188 investigation and management in amiodarone-induced PPAR-ygene 102 156-7 thyrotoxicosis 23, 24 Prader-Willi syndrome 126 in lithium therapy 217 multinodular goitre 9 prazosin, use in primary hypoparathyroidism 158, in thyroid cancer 13 phaeochromocytoma 171 thyrotoxicosis 3,5,8

worsening of thyrotoxicosis 40,42	for thyroid disease during	of amiodarone 22
radiofrequency ablation surgery 25	pregnancy 37	of HRT 225
radiographic contrast media, use in	SDH gene mutations,	of lithium 215
thyrotoxic crisis 41	paraganglionomas 171–2	of radioactive iodine treatment
radiosurgery, for non-functioning	secondary amenorrhoea 99	9
pituitary adenoma 87	assessment 100, 101	of somatostatin analogues 78
radiotherapy	causes 100	of thionamide drugs 2, 8-9,
for acromegaly 78	polycystic ovarian syndrome	210-13
for Cushing's disease 66	100–3	sildenafil 120-1, 122
for non-functioning pituitary	premature ovarian failure 109,	interaction with amiodarone 22
adenomas 86–7	112	silent corticotroph adenomas
for prolactinoma 82	secondary hyperaldosteronism	(SCAs) 66–7
for thyroid eye disease 46	174	simvastatin, interaction with
RALES (Randomised Aldactone	secondary hyperparathyroidism	amiodarone 22
Evaluation Study) 177	154	single photon emission computed
raloxifene	secondary hypertension 164	tomography (SPECT), adrenal
MORE trial 225	endocrine causes 164-6	tumours 61
value in gynaecomastia 140	Conn's syndrome 174–8	skin rashes, as side effect of
reactive hypoglycaemia 200–1	mineralocorticoid	thionamide drugs 2
recurrence rate, prolactinoma 82	hypertension 167–8	skin reactions, thionamide drugs
recurrent laryngeal nerve palsy 7	phaeochromocytoma 167,	210
5α-reductase deficiency 127	169–73	skull X-rays, value in acromegaly 76
Reifenstein's syndrome 127	selective androgen receptor	Slow K 188
renal abnormalities	modulators 129	smoking, risk of thyroid disease 3,
lithium as cause 215–17	selective oestrogen receptor	36–7,46
in Turner's syndrome 143	modulators 225	sodium balance 179–80
renal artery stenosis 164–5	semen analysis, in male	see also hyponatraemia
renal disease	hypogonadism 126	sodium chloride, suppression of
effect on vitamin D metabolism	Sertoli cell only syndrome 127	aldosterone 175
219	sex hormone-binding globulin	sodium iodide, use in thyrotoxic
gynaecomastia 136	(SHBG) levels in hirsutism 114	crisis 40
renin levels, in Addison's disease 206	levels in Klinefelter's syndrome	SOM230 79
respiratory disorders, in acromegaly	149	somatostatin, and thyroid eye disease 47
70	levels in PCOS 100	somatostatin analogues
retinoic acid, in treatment of	sex hormone replacement in	use in acromegaly 78
Cushing's disease 67	hypopituitarism 92	use in non-functioning pituitary
retrosternal goitre 7	sex steroid deficiency, risk of	adenoma 87
retrovirus-derived human genome	adrenal crisis 53	somatostatin receptors,
elements 56	SF-1 mutations 53	somatotroph adenomas 76
rosiglitazone, in management of	shaving 116	sperm cryopreservation in
PCOS 102, 105	short stature, in Turner's syndrome	Klinefelter's syndrome 149,
roux-en-Y gastric bypass,	142	150
hypoglycaemia 203	short Synacthen test (SST) 52	spironolactone
RU-486 67	in acromegaly 76	use in Conn's syndrome 177,
100 07	in congenital adrenal hyperplasia	178
5	71,72	use in hirsutism 117, 118
SAME (syndrome of apparent	SIADH (syndrome of inappropriate	stearoyl CoA desaturase 47
mineralocorticoid excess)	ADH secretion) 181, 183,	stem cells, differentiation into
168, 188	184	oocytes 111
Sando-K 188	sibutramine 105	steroid-secreting cells,
Schmidt's syndrome 55	sick euthyroid syndrome 16, 19, 20	autoantibodies 110
screening	patterns of abnormality 17	steroid suppression, in hirsutism
for 21-hydroxylase deficiency 72	side chain cleavage (SCC) enzyme	114,117
for phaeochromocytoma 170,	antibodies 56	steroidogenic acute regulatory
171	side effects	protein deficiency 72



121

tadalafil 120-1,122

Index

steroids tamoxifen, value in gynaecomastia management 13, 15 papillary 12,14 relative potencies 206 side effects 206-7 tarsorrhaphy 46 post-partum thyroid disturbance synthesis in adrenal glands 50 telogen 113 as risk factor 37 use in amiodarone-induced terlipressin, stimulation of cortisol thyroid dysfunction, relationship to thyrotoxicosis 24,26 production 62 thyroid eye disease 46 use in hyperemesis gravidarum testicular biopsy 126 thyroid eye disease (TED) 43 32 in Klinefelter's syndrome 149, clinical features 44 use in non-classic congenital pathogenesis 43-4,45 150 adrenal hyperplasia 72 testicular feminisation 127 treatment 44,46-7 use in thyroid eye disease 46, 47 testicular tumours, gynaecomastia thyroid function use in thyrotoxic crisis 40 in acromegaly 76 testicular volume, in Klinefelter's changes during pregnancy stress response, abnormal in hypopituitarism 91 syndrome 148 31 - 2stroke, risk from HRT 224, 225 testolactone, value in effects of amiodarone 23-4, gynaecomastia 140 subclinical autonomous 25-6 glucocorticoid hypersecretion testosterone in premature ovarian failure 111 as cause of gynaecomastia 138 (SAGH) 62 prognostic value in critical subclinical hypothyroidism 27-30 deficiency in Klinefelter's disease 16,19 subfertility, management in PCOS syndrome 148-9 in Turner's syndrome 143, 145 levels in hypogonadism 125 thyroid hormone, transportation in testosterone therapy succinate dehydrogenase complex plasma 17-18 gene mutations 167,170 available preparations 129 thyroid hormone receptors 19 surgery in delayed puberty 134 thyroid hormone resistance 19 in acromegaly 76-8 in erectile dysfunction 123-4 thyroid hormone replacement in Conn's syndrome 177 in hypopituitarism 92 228-31 for gynaecomastia 140 in male hypogonadism 127-8 thyroid nodules 11,15 in hyperparathyroidism 156 in women 224, 225 differential diagnosis 14 for insulinoma 201 see also androgen replacement investigation 11-12 management of adrenal therapy see also thyroid cancer insufficiency 53-4 theophylline, interaction with thyroid stimulating hormone amiodarone 22 minimally invasive, thyroid (TSH) lesions 10, 15 thiazide diuretics 180 changes during pregnancy and erectile dysfunction 124 31-2 for non-functioning pituitary adenomas 85-6 in lithium-induced diabetes deficiency, clinical features 91 for phaeochromocytoma 171 insipidus 217 levels in adrenal crisis 53 precipitation of thyrotoxic crisis use in hypertension 164 suppression in thyroid cancer thiazolidinediones, use in PCOS in prolactinoma 82 102, 105, 107, 117 TSH receptor 3 for thyroid eye disease 46 thionamide drugs 2, 4, 8-9, 10 TSH receptor antibodies, thyroid Sustanon 127 side effects 210-13 eye disease 44,46 Synacthen tests 52,53 use in amiodarone-induced thyroid storm 39-40 in hirsutism 114 thyrotoxicosis 24 differential diagnosis 40 management 40-2 syndrome of apparent use during pregnancy 33 mineralocorticoid excess use in thyroid eye disease 47 thyroid tests, interpretation 20 thyroid tissue (SAME) 168,188 use in thyrotoxic crisis 40 systemic lupus erythematosus, thyroglobulin 3 autotransplantation 9 association with miscarriage monitoring in thyroid cancer 13, thyroidectomy 9 30 minimally invasive video-assisted thyroid, sick euthyroid syndrome (MIVAT) 10 16 - 20parathyroid gland damage 162, T, see triiodothyronine thyroid artery embolization 9 219 T, see thyroxine thyroid cancer 7 for thyroid cancer 13 tachyphylaxis, PDE-5 inhibitors and amiodarone 23 thyrotoxic crisis 39-40

fine needle aspiration cytology

(FNAC) 11-12

differential diagnosis 40

management 40-2

thyrotoxicosis 1–2 amiodarone-induced (AIT) 23–4	transthyretin (TTR) 17-18 traumatic brain injury (TBI) diabetes insipidus 195, 197-8,	verapamil, use in insulinoma 201 virilising adrenal tumours 59,60 visual field defects, pituitary
management 24, 25 colour Doppler sonography 5	199 hypopituitarism as complication	adenomas 86 visual function, recovery after
during pregnancy 33,37	93,94	treatment of pituitary
familial periodic paralysis 186	triamcinolone, potency 206	adenoma 87,88
genetics of Grave's disease 3	triamterene 180, 187	vitamin A supplements, value in
gynaecomastia 136	triiodothyronine (T ₃) 18	delayed puberty 134
hypertension 165	changes during pregnancy 31	vitamin D deficiency 158, 159
investigations 5	effect of amiodarone 23	causes 220
in post-partum thyroid disturbance 35	as prognostic factor in cardiac failure 19	vitamin D levels, health aspects 222 vitamin D metabolism 219, 220
risk factors for Graves' disease	replacement therapy 228-9, 230,	vitamin D receptor 3
3,5	231	vitamin D supplementation 221-2
thionamide drug treatment	T ₃ response elements 19	vocal cord paralysis, risk after
2-3,4	trilostane therapy, Cushing's disease	thyroidectomy 9
side effects 210–13 treatment of subclinical disease	66	von Hippel-Lindau disease,
	trimegestone 225	phaeochromocytoma 167, 170
7-8	triple A (Allgrove's) syndrome 52	von Willebrand's disease 197
thyrotropin-releasing hormone	triple therapy, for erectile dysfunction 121	von willedrand salsease 157
(TRH) test in acromegaly 76	Trousseau's sign 159–60	W
in prolactinoma 81	tryptophan hydrolase antibodies 56	warfarin, interaction with
thyroxine	tuberculosis, adrenal cortex	amiodarone 22
changes during pregnancy 31	destruction 50,53	water balance 194
combination with anti-thyroid	Turner's syndrome	water deprivation test 196-7, 199,
drugs 2–3	clinical features 142-3	217
effect of amiodarone 23	management 144, 145-6	weight loss
metabolism 18-19		in Grave's discase 1
replacement therapy 228-31	U	value in PCOS 105
dose requirements during	ultrasound scans, incidental adrenal	Wernicke's encephalopathy, in
pregnancy 29, 30	tumours 59,60	thyrotoxic crisis 39
in hypopituitarism 91-2	urine, screening tests for	Wolff-Chaikoff effect 23,40
overdose 39-40, 41	phaeochromocytoma 60,170	Wolfram's syndrome (DIDMOAD)
in post-partum thyroid	urine free cortisol 64	195
disturbance 35-6, 38		Women's Health Initiative (WHI)
in thyroid cancer 13	V	225
thyroxine-binding globulin (TBG) 17	vacuum tumescence devices 121	WT-1 53
changes during pregnancy 31	vaginal oestrogen therapy 224	V
thyroxine-binding pre-albumin	valproate, association with PCOS 102	X X II de de de cellemente de la
(transthyretin) 17–18	vanillylmandelic acid (VMA),	X-linked adrenal hypoplasia
tibolone 129,224	urinary 60, 170	congenital 50
tolyaptan 183	vardenafil 120–1, 122	X-linked adrenoleukodystrophy 50 X-linked hypoparathyroidism 160
toxic thyroid adenoma 6,39	vasculitis, as side effect of	A-mikeu nypopatamytoidism 100
trans-sphenoidal surgery	thionamide drugs 212–13	Υ
in acromegaly 76,78	vasopressin see arginine vasopressin	Y85C mutation 55
in Cushing's disease 66	venlafaxine, in treatment of	1 Je G Hawiigh OF
for non-functioning pituitary adenomas 85–6	menopausal symptoms 224	Z
adenomas 85-0		
transcutaneous testosterone	venous thromboembolism, risk	zona pellucida, autoantibodies